## First-Line Anti-VEGF for Clinically Significant Diabetic Macular Edema **Key Point:** Intravitreal ranibizumab is the first-line pharmacological treatment for CSME in NPDR, with robust evidence from the RESTORE and RISE/RIDE trials. ### Definition of Clinically Significant Macular Edema (CSME) CSME is present when: 1. Retinal thickening within 500 μm of the foveal center, OR 2. Hard exudates within 500 μm of the fovea with adjacent retinal thickening, OR 3. Retinal thickening ≥1 disc diameter in size and within 1 disc diameter of the fovea ### Why Ranibizumab Is First-Line ```mermaid flowchart TD A["NPDR with CSME"]:::outcome --> B{"Prior anti-VEGF treatment?"}:::decision B -->|"No"| C["First-line: Intravitreal anti-VEGF"]:::action C --> D{"Which anti-VEGF?"}:::decision D -->|"FDA-approved, RCT evidence"| E["Ranibizumab 0.5 mg"]:::action D -->|"Off-label, cost-effective"| F["Bevacizumab 1.25 mg"]:::action D -->|"Newer, longer interval"| G["Aflibercept 2 mg"]:::action B -->|"Yes, failed"| H["Consider corticosteroid or switch anti-VEGF"]:::action ``` **High-Yield:** Ranibizumab is the **gold-standard first-line agent** because: - FDA-approved specifically for DME - RESTORE trial: ranibizumab monotherapy superior to laser alone - RISE/RIDE trials: sustained visual improvement over 3 years - Monthly dosing with PRN or treat-and-extend regimens ### Ranibizumab Dosing for DME - **Loading phase:** 0.5 mg intravitreal injection monthly × 3 months - **Maintenance:** PRN (as-needed) or TAE (treat-and-extend) protocol - **Response:** Mean improvement in BCVA ~7–10 letters by month 12 - **Central retinal thickness:** Reduction of 100–150 μm by month 3 ### Comparison of Intravitreal Agents for CSME | Agent | Class | Status | Onset | Interval | First-Line? | |-------|-------|--------|-------|----------|-------------| | **Ranibizumab** | **Anti-VEGF** | **FDA-approved** | **2–4 weeks** | **Monthly/PRN** | **YES** | | Bevacizumab | Anti-VEGF | Off-label | 2–4 weeks | Every 4–6 weeks | No (cost-driven) | | Aflibercept | Anti-VEGF | FDA-approved | 2–4 weeks | Every 8 weeks | No (newer, less data) | | Triamcinolone | Corticosteroid | Off-label | 1–2 weeks | Every 3–4 months | No (2nd-line) | | Dexamethasone implant | Corticosteroid | FDA-approved | 1–2 weeks | Every 5 months | No (2nd-line) | **Clinical Pearl:** In this patient with NPDR and CSME, anti-VEGF monotherapy is preferred over laser photocoagulation or corticosteroids because: 1. Ranibizumab improves vision more than laser alone 2. Avoids cataract risk (unlike steroids) 3. Better safety profile in NPDR (no risk of neovascularization paradox) **Warning:** Do not use corticosteroids as first-line in NPDR—they increase cataract risk and are reserved for: - DME with concurrent uveitis - Anti-VEGF failure or intolerance - Proliferative DR with severe macular edema (off-label) ### When to Switch or Add Therapy - **Inadequate response at 3 months:** Consider switching to aflibercept or adding corticosteroid - **Recurrent edema on PRN:** Switch to treat-and-extend or fixed monthly dosing - **Intolerance to anti-VEGF:** Corticosteroid implant (dexamethasone or triamcinolone)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.